Pemakaian Nikotinamide Dalam Penanganan Hiperfosfatemia Pada Pasien Hemodialisis

(1)

(2)

LAMPIRAN 2

LEMBARAN PENJELASAN

Assalamualaikum wr.wb,

Salam sejahtera bagi Bapak/Ibu,

Terima kasih atas kesediaan Bapak/Ibu meluangkan waktu untuk

membaca dan mengisi surat persetujuan ini, sebelumnya, perkenankan saya

memperkenalkan diri. Nama saya dr. Meivina Ramadhani Pane, Peserta Program

Pendidikan Dokter Spesialis Ilmu Penyakit Dalam di Fakultas Kedokteran

Universitas Sumatera Utara (FK-USU). Saya sedang melakukan pengumpulan

data penelitian tugas akhir sebagai salah satu syarat menyelesaikan pendidikan di

FK-

USU. Adapun judul penelitian saya adalah ―Efika

si dan keamanan

n

ikotinamide dalam penanganan hiperfosfatemia pada pasien hemodialisis‖

Penelitian ini bertujuan untuk mengetahui efektivitas dan keamanan

penggunaan Nikotinamide dalam menurunkan kadar fosfat darah pada pasien cuci

darah dengan harga yang relatif lebih murah dibandingkan dengan obat yang

sudah ada sebelumnya di pasaran.

Penelitian ini dimulai dengan pengambilan sampel darah vena sebanyak ±

2 sendok makan yang dilakukan sebelum hemodialisis dimulai. Sampel darah ini

digunakan untuk pemeriksaan darah rutin, LFT, RFT, fosfat, kalsium, albumin,

dan profil lipid. Kemudian apabila kadar serum fosfat pasien ≥ 5.5 mg/dl, maka

akan diberikan kapsul nikotinamide 250 mg 2 kali sehari pada pagi dan petang

hari pada saat makan. Kemudian setelah 4 minggu dan 8 minggu dilakukan

pengambilan darah kembali untuk menilai darah rutin, fosfat, kalsium, fungsi hati,

(3)

Penelitian ini tidak berbahaya, pada saat pengambilan darah dapat timbul

lebam pada bekas tempat pengambilan yang akan hilang sendiri dalam satu atau

dua hari. Sementara nikotinamide berdasarkan pengalaman selama ini belum

pernah menunjukkan bahaya yang serius. Beberapa efek samping yang mungkin

terjadi dari pemberian obat ini adalah diare, penurunan kadar trombosit dan

kemerahan pada wajah. Namun efek samping tersebut akan hilang jika dosis obat

dikurangi. Efek samping obat tersebut biasanya terjadi jika diberikan dengan dosis

tinggi, sedangkan pada penelitian ini dosis obat yang diberikan adalah 500 mg per

hari. Segala biaya pemeriksaan laboratorium, penyediaan obat dan biaya

penanganan yang diperlukan bila timbul efek samping akan menjadi tanggung

jawab peneliti.

Terimakasih atas keikutsertaan Bapak/Ibu. Apabila ada hal-hal yang

terjadi selama penelitian dan ada keterangan yang saya berikan masih belum jelas

atau yang ingin ditanyakan, Bapak/Ibu dapat menghubungi saya :

Nama : dr. Meivina Ramadhani Pane

Alamat : Jl. Suka Ramai No.4 Medan

No Telp : 081260297727

Atas perhatian Bapak/Ibu saya ucapkan terima kasih.

Hormat saya,

(4)

LAMPIRAN 3

LEMBAR PERSETUJUAN SETELAH PENJELASAN

(

INFORMED CONSENT

)

=======================================================

No. Peserta :

Saya yang bertanda tangan di bawah ini :

Nama

:

Umur

:

tahun

Jenis Kelamin

: Laki-laki / Perempuan *

Alamat

:

No. Telepon

:

Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan

prosedur penelitian ini, menyatakan bersedia untuk ikut dalam penelitian tentang :

―

EFIKASI DAN KEAMANAN NIKOTINAMIDE DALAM PENANGANAN

HIPERFOSFATEMIA PADA PASIEN HEMODIALISIS

‖.

Demikian surat pernyataan bersedia ikut dalam penelitian ini saya perbuat

untuk dapat digunakan seperlunya.

Medan, 2013

Peneliti,

Pasien,

( dr. Meivina Ramadhani Pane )

(...)

Saksi,

(5)

LAMPIRAN 4

KERTAS KERJA PROFIL PESERTA PENELITIAN

I. IDENTITAS PRIBADI

Nama

:

Umur

: tahun

Jenis Kelamin

: pria/wanita

Riwayat penyakit

: DM/hipertensi/batu ginjal/kista

HD sejak

:

II. HASIL PEMERIKSAAN LABORATORIUM

Parameter

Sebelum

Minggu ke-4

Minggu Ke-8

Fosfat (mg/dl)

Kalsium (mg/dl)

Fosfat x kalsium

(mg

2

/dl

2

)

Trombosit (x10

3

/mm

3

)

SGOT (U/L)

SGPT (U/L)

HDL (mg/dl)

LDL (mg/dl)

(6)

LAMPIRAN 5

Data Penelitian Sebelum Pemberian Nikotinamide

Pasien Umur JK Fosfat Kalsium CaxP Trombosit SGOT SGPT HDL LDL (THN) (mg/dl) (mg/dl) (mg2/dl2) (103/mm3) (U/L) (U/L) (mg/dl) (mg/dl)

1

54 P

7

9.2

64.4

179

23

22

43

131

2

55 P

7

10.3

72.1

186

31

45

38

83

3

38 L

7.2

8.6

61.9

147

45

16

33

64

4

70 L

6.3

9.8

61.74

160

51

37

35

101

5

40 L

7.9

9.1

71.89

340

23

15

23

123

6

53 L

6.3

9.9

62.37

157

34

49

34

99

7

43 L

11.3

9

101.7

130

20

50

37

60

8

46 L

8.1

9.6

77.76

123

18

13

38

138

9

41 L

9.2

10.3

94.76

213

65

11

33

113

10

59 L

9.5

9.6

91.2

284

71

45

50

99

11

43 L

9.5

10.3

97.85

331

16

10

49

99

12

35 L

9

10

90

173

34

43

37

78

13

38 L

7.3

10.6

77.38

263

19

14

64

143

14

44 L

9.9

9.1

90.09

167

18

17

56

110

15

42 P

7.4

8.8

65.12

230

31

29

54

109

16

32 L

9.5

9.3

88.35

165

37

48

28

88

17

54 P

6.2

11.5

71.3

237

41

51

49

69 Data Penelitian Setelah Minggu ke-4 Pemberian Nikotinamide

1

54 P

9.7

8.6

83.42

146

28

20

41

123

2

55 P

8

10.6

84.8

221

23

41

68

3

38 L

5.5

8.7

47.85

172

23

40

34

77

4

70 L

5.7

9.8

55.86

165

38

35

37

98

5

40 L

8

8.4

67.2

228

22

25

27

149

6

53 L

5.7

8.2

46.74

166

18

30

25

105

7

43 L

10.6

7.5

79.5

125

44

63

44

63

8

46 L

7.6

8.8

66.88

129

12

22

35

112

9

41 L

8.3

10

83

198

20

17

38

116

10

59 L

6.6

9

59.4

246

33

35

44

110

11

43 L

8.1

10.2

82.62

243

20

13

35

70

12

35 L

5.6

8.6

48.16

170

35

44

38

81

13

38 L

7

10.7

74.9

283

19

13

53

98

14

44 L

10.2

8.9

90.78

195

17

56

104

15

42 P

6.5

8.3

53.95

200

32

35

20

97

16

32 L

9.3

8.2

76.26

282

45

55

38

90

(7)

Data Penelitian Setelah Minggu ke-8 Pemberian Nikotinamide

1

54 P

7.8

8.2

63.96

258

34

23

41

120

2

55 P

7.9

10.9

86.11

251

21

31

39

64

3

38 L

5.2

8.8

45.76

165

22

35

78

4

70 L

3.4

9.6

32.64

160

28

21

41

95

5

40 L

6.9

8.7

60.03

348

20

23

30

139

6

53 L

5.1

8.5

43.35

170

20

28

30

97

7

43 L

9.6

8.8

84.48

167

12

19

42

76

8

46 L

5.3

8.6

45.58

159

13

20

40

125

9

41 L

7.2

10

72

189

16

10

45

110

10

59 L

5.1

8.7

44.37

230

30

40

48

125

11

43 L

8.5

9.7

82.45

252

18

10

30

75

12

35 L

5.5

8.3

45.65

161

34

37

75

13

38 L

7.9

10

70

287

19

13

37

124

14

44 L

9.9

8.2

81.18

158

27

55

76

103

15

42 P

6.3

8.5

53.55

232

32

33

39

146

16

32 L

9.1

82.81

249

23

29

26

79

17

54 P

2.7

11.7

31.59

155

35

27

35

77 Keterangan:

P : Perempuan

(8)

LAMPIRAN 6

OUTPUT ANALISIS

Jk

Frequency Percent Valid Percent

Cumulative

Frequency Percent Valid Percent

Cumulative

(9)

Descriptives

Statistic Std. Error Umur Mean 46,2941 2,38371

95% Confidence Interval for Mean

Lower Bound 41,2409 Upper Bound 51,3474 5% Trimmed Mean 45,7712 Median 43,0000 Variance 96,596 Std. Deviation _9,82831

Minimum _32,00

Maximum 70,00

Range 38,00

Interquartile Range 15,00

Skewness ,835 ,550 Kurtosis ,512 1,063 Lama HD (tahun) Mean 4,2453 ,59815

Lower Bound 2,9773 Upper Bound _5,5133 5% Trimmed Mean 4,1798

Median 4,0000

Variance 6,082 Std. Deviation 2,46622

Minimum _,67

Maximum 9,00

Range 8,33

Interquartile Range _4,25

Skewness ,448 ,550 Kurtosis -,760 1,063 Ca1 Mean 9,7059 ,18119

Lower Bound 9,3218 Upper Bound 10,0900 5% Trimmed Mean _9,6676

Median 9,6000

Variance ,558

Std. Deviation _,74705

Minimum 8,60

Maximum 11,50

Range _2,90

Skewness ,690 ,550 Kurtosis ,484 1,063 Ca2 Mean 9,1294 ,24235

(10)

Variance ,998 Std. Deviation ,99923

Minimum _7,50

Maximum 10,70

Range 3,20

Skewness ,412 ,550 Kurtosis -1,059 1,063 Ca3 Mean 9,1941 ,24109

Median 8,8000

Variance ,988

Std. Deviation _,99403

Minimum 8,20

Maximum 11,70

Range 3,50

Skewness 1,300 ,550 Kurtosis 1,211 1,063 Fosfat1 Mean 8,1529 ,36290

Median _7,9000

Minimum _6,20

Maximum 11,30

Range 5,10

Skewness ,432 ,550 Kurtosis -,708 1,063 Fosfat2 Mean 7,5412 ,40900

Median 7,6000

Variance 2,844 Std. Deviation _1,68636

Minimum 5,50

Maximum 10,60

Range 5,10

Skewness ,414 ,550 Kurtosis -1,010 1,063 Fosfat3 Mean 6,6706 ,50670

(11)

Mean Upper Bound 7,7447 5% Trimmed Mean 6,7118

Median _6,9000

Minimum _2,70

Maximum 9,90

Range 7,20

Skewness -,219 ,550 Kurtosis -,693 1,063 CaxFosfat1 Mean 78,8182 3,33926

Lower Bound 71,7393 Upper Bound 85,8972 5% Trimmed Mean _78,4958 Median 77,3800 Variance 189,561 Std. Deviation 13,76813

Minimum 61,74

Maximum _101,70

Range 39,96

Skewness ,207 ,550 Kurtosis -1,479 1,063 CaxFosfat2 Mean 68,4341 3,55116

Lower Bound _60,9060 Upper Bound 75,9622 5% Trimmed Mean 68,3979 Median _67,2000 Variance 214,383 Std. Deviation 14,64183

Minimum _46,74

Maximum 90,78

Range 44,04

Skewness -,143 ,550 Kurtosis -1,428 1,063 CaxFosfat3 Mean 60,3241 4,59669

Lower Bound 50,5796 Upper Bound 70,0687 5% Trimmed Mean _60,4879 Median 60,0300 Variance 359,203 Std. Deviation 18,95265

Minimum 31,59

Maximum 86,11

Range 54,52

(12)

Skewness ,015 ,550 Kurtosis -1,503 1,063 Trombosit1 Mean 205,00 16,107

Lower Bound _170,85 Upper Bound 239,15 5% Trimmed Mean _202,06

Median 179,00

Minimum 123

Maximum 340

Range ₂₁₇

Interquartile Range 92

Skewness ,883 ,550 Kurtosis -,194 1,063 Trombosit2 Mean 199,06 11,614

Median 198,00

Variance _2293,059 Std. Deviation 47,886

Minimum 125

Maximum ₂₈₃

Range 158

Interquartile Range ₇₀

Skewness ,238 ,550 Kurtosis -,670 1,063 Trombosit3 Mean 211,24 13,859

Lower Bound _181,85 Upper Bound 240,62 5% Trimmed Mean _206,76

Median 189,00

Minimum 155

Maximum 348

Range ₁₉₃

Skewness ,872 ,550 Kurtosis ,148 1,063 SGOT1 Mean 33,94 3,983

Median 31,00

(13)

Maximum 71

Range 55

Interquartile Range ₂₄

Skewness 1,039 ,550 Kurtosis ,435 1,063 SGOT2 Mean 26,82 2,336

Median 23,00

Minimum 12

Maximum 45

Range ₃₃

Skewness ,568 ,550 Kurtosis -,577 1,063 SGOT3 Mean 23,76 1,800

Median 22,00

Minimum ₁₂

Maximum 35

Range 23

Interquartile Range ₁₃

Skewness ,121 ,550 Kurtosis -1,172 1,063 SGPT1 Mean 30,29 3,908

Median 29,00

Minimum 10

Maximum 51

Range ₄₁

Skewness ,049 ,550 Kurtosis -1,931 1,063 SGPT2 Mean 31,06 3,505

(14)

Minimum ₁₃

Maximum 63

Range 50

Interquartile Range ₂₂

Skewness ,708 ,550 Kurtosis -,039 1,063 SGPT3 Mean 26,71 2,797

Median 27,00

Minimum 10

Maximum 55

Range 45

Skewness ,649 ,550 Kurtosis ,917 1,063 HDL1 Mean 41,24 2,637

Median _38,00

Minimum ₂₃

Maximum 64

Range 41

Interquartile Range ₁₆

Skewness ,461 ,550 Kurtosis -,323 1,063 HDL2 Mean 37,24 2,268

Median 38,00

Minimum 20

Maximum 56

Range 36

Skewness ,182 ,550 Kurtosis ,191 1,063 HDL3 Mean 39,47 2,679

(15)

Mean Upper Bound 45,15 5% Trimmed Mean 38,19

Median _39,00

Minimum ₂₆

Maximum 76

Range 50

Interquartile Range ₉

Skewness 2,331 ,550 Kurtosis 7,628 1,063 LDL1 Mean 100,41 6,035

Median 99,00

Minimum 60

Maximum ₁₄₃

Range 83

Skewness ,047 ,550 Kurtosis -,753 1,063 LDL2 Mean 96,88 5,356

Lower Bound _85,53 Upper Bound 108,24 5% Trimmed Mean 95,87

Median _98,00

Minimum ₆₃

Maximum 149

Range 86

Interquartile Range ₃₂

Skewness ,507 ,550 Kurtosis ,494 1,063 LDL3 Mean 100,47 6,236

Lower Bound _87,25 Upper Bound 113,69 5% Trimmed Mean 99,97

Median 97,00

Minimum ₆₄

Maximum ₁₄₆

(16)

Skewness ,299 ,550 Kurtosis -1,276 1,063

Tests of Normality

Kolmogorov-Smirnova Shapiro-Wilk Statistic df Sig. Statistic df Sig. *. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Wilcoxon Signed Ranks Test

(17)

i. Ca3 = Ca2

Test Statisticsa

Ca2 - Ca1 Ca3 - Ca1 Ca3 - Ca2 Z -3,029b -2,875b -,104c Asymp. Sig. (2-tailed) ,002 ,004 ,917 a. Wilcoxon Signed Ranks Test

b. Based on positive ranks. c. Based on negative ranks.

Friedman Test

Ranks

Mean Rank Fosfat sebelum pemberian

Niacinamide, mg/dl 2,56 Fosfat setelah pemberian

Niacinamide 4 minggu, mg/dl

2,12

Fosfat setelah pemberian Niacinamide 8 minggu, mg/dl

1,32

N 17

Chi-Square 13,522

df 2

Asymp. Sig. ,001 a. Friedman Test

General Linear Model

Within-Subjects Factors Measure: MEASURE_1

Fosfat Dependent Variable 1 Fosfat1 a. Design: Intercept

(18)

Mauchly's Test of Sphericitya Measure: MEASURE_1

Within Subjects

Effect Mauchly's W

Approx.

Chi-Square df Sig.

Epsilonb

Greenhouse-Geisser Huynh-Feldt Lower-bound Fosfat ,814 3,093 2 ,213 ,843 ,931 ,500 Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent

variables is proportional to an identity matrix. a. Design: Intercept

Within Subjects Design: Fosfat

b. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

Tests of Within-Subjects Effects Measure: MEASURE_1

Source

Type III Sum of

Squares df Mean Square F Sig. Fosfat Sphericity Assumed 18,867 2 9,434 10,213 ,00

Greenhouse-Geisser 18,867 1,686 11,191 10,213 ,00 Huynh-Feldt 18,867 1,863 10,130 10,213 ,00 Lower-bound 18,867 1,000 18,867 10,213 ,00 Error(Fosfat) Sphericity Assumed 29,559 32 ,924

Greenhouse-Geisser 29,559 26,974 1,096 Huynh-Feldt 29,559 29,800 ,992 Lower-bound 29,559 16,000 1,847

Tests of Within-Subjects Contrasts Measure: MEASURE_1

Source Fosfat

Type III Sum of

Tests of Between-Subjects Effects Measure: MEASURE_1

Transformed Variable: Average

Source

Type III Sum of

(19)

Estimated Marginal Means

Fosfat

Estimates Measure: MEASURE_1

Fosfat Mean Std. Error

95% Confidence Interval Lower Bound Upper Bound 1 8,153 ,363 7,384 8,922

95% Confidence Interval for Differenceb

Lower Bound Upper Bound 1 2 ,612 ,333 ,255 -,279 1,503 Based on estimated marginal means

*. The mean difference is significant at the ,05 level. b. Adjustment for multiple comparisons: Bonferroni.

Multivariate Tests Each F tests the multivariate effect of Fosfat. These tests are based on the linearly

independent pairwise comparisons among the estimated marginal means. a. Exact statistic

General Linear Model

Within-Subjects Factors KalsiumxFosfat Pillai's Trace ,596 11,069b 2,000 15,000 ,001

Wilks' Lambda ,404 11,069b 2,000 15,000 ,001 Hotelling's Trace 1,476 11,069b 2,000 15,000 ,001 Roy's Largest Root 1,476 11,069b 2,000 15,000 ,001 a. Design: Intercept

(20)

b. Exact statistic

Within Subjects

Effect Mauchly's W

Approx.

Chi-Square df Sig.

Epsilonb

Greenhouse-Geisser Huynh-Feldt Lower-bound KalsiumxFosfat ,803 3,300 2 ,192 ,835 ,921 ,500 Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. Design: Intercept

Within Subjects Design: KalsiumxFosfat

Source

Type III Sum of

Squares df Mean Square F Sig. KalsiumxFosfat Sphericity Assumed 2921,928 2 1460,964 15,250 ,000

Greenhouse-Geisser 2921,928 1,670 1749,487 15,250 ,000 Huynh-Feldt 2921,928 1,842 1586,448 15,250 ,000 Lower-bound 2921,928 1,000 2921,928 15,250 ,001 Error(KalsiumxFosfat) Sphericity Assumed 3065,571 32 95,799

Greenhouse-Geisser 3065,571 26,723 114,718 Huynh-Feldt _{3065,571 29,469} _104,027 Lower-bound _{3065,571 16,000} _191,598

Source KalsiumxFosfat

Type III Sum of

Squares df Mean Square F Sig KalsiumxFosfat Linear 2907,275 1 2907,275 22,613

Quadratic 14,653 1 14,653 ,232 Error(KalsiumxFosfat) Linear _2057,088 ₁₆ _128,568

Quadratic _1008,483 ₁₆ _63,030

Source

Type III Sum of

(21)

Estimated Marginal Means

KalsiumxFosfat

KalsiumxFosfat Mean Std. Error

95% Confidence Interval Lower Bound Upper Bound 1 78,818 3,339 71,739 85,897

xFosfat (J) KalsiumxFosfat

Mean Difference

(I-J) Std. Error Sig.b

95% Confidence Interval for Differenceb

Lower Bound Upper Bound 1 2 10,384* 3,480 ,026 1,081 19,687 Based on estimated marginal means

*. The mean difference is significant at the ,05 level. b. Adjustment for multiple comparisons: Bonferroni.

Multivariate Tests Each F tests the multivariate effect of KalsiumxFosfat. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means.

a. Exact statistic

Friedman Test

Ranks

Mean Rank Trombosit sebelum pemberian Niacinamide, mg/dl 1,91 Trombosit setelah pemberian Niacinamide 4 minggu, mg/dl 1,94 Trombosit setelah pemberian Niacinamide 8 minggu, mg/dl 2,15

N 17

Chi-Square ,567

df 2

(22)

Friedman Test

Ranks

Mean Rank SGOT sebelum pemberian Niacinamide, mg/dl 2,32 SGOT setelah pemberian Niacinamide 4 minggu, mg/dl 2,03 SGOT setelah pemberian Niacinamide 8 minggu, mg/dl 1,65

N 17

Chi-Square 4,290

df 2

Friedman Test

Ranks

Mean Rank SGPT sebelum pemberian Niacinamide, mg/dl 2,06 SGPT setelah pemberian Niacinamide 4 minggu, mg/dl 2,29 SGPT setelah pemberian Niacinamide 8 minggu, mg/dl 1,65

N 17

Chi-Square 3,815

df 2

Friedman Test

Ranks

Mean Rank HDL sebelum pemberian Niacinamide, mg/dl 2,00 HDL setelah pemberian Niacinamide 4 minggu, mg/dl 1,88 HDL setelah pemberian Niacinamide 8 minggu, mg/dl 2,12

N 17

Chi-Square ,492

df 2

(23)

General Linear Model

Within-Subjects Factors Measure: MEASURE_1

LDL Dependent Variable 1 LDL1 a. Design: Intercept

Within Subjects Design: LDL b. Exact statistic

Within Subjects

Effect Mauchly's W

Approx.

Chi-Square df Sig.

Epsilonb

Greenhouse-Geisser Huynh-Feldt Lower-bound LDL ,976 ,360 2 ,835 ,977 1,000 ,500 Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. Design: Intercept

Within Subjects Design: LDL

Source

Type III Sum of

Squares df Mean Square F Sig. LDL Sphericity Assumed 143,569 2 71,784 ,505 ,608

Greenhouse-Geisser 143,569 1,954 73,486 ,505 ,604 Huynh-Feldt 143,569 2,000 71,784 ,505 ,608 Lower-bound 143,569 1,000 143,569 ,505 ,487 Error(LDL) Sphericity Assumed 4547,765 32 142,118

Greenhouse-Geisser 4547,765 31,259 145,486 Huynh-Feldt 4547,765 32,000 142,118 Lower-bound 4547,765 16,000 284,235

(24)

Source

Type III Sum of

Squares df Mean Square F Sig. Intercept 502428,314 1 502428,314 338,616 ,000 Error 23740,353 16 1483,772

Estimated Marginal Means

LDL

LDL Mean Std. Error

95% Confidence Interval Lower Bound Upper Bound 1 100,412 6,035 87,617 113,206

95% Confidence Interval for Differencea

Lower Bound Upper Bound 1 2 3,529 4,343 1,000 -8,079 15,138 Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Multivariate Tests Each F tests the multivariate effect of LDL. These tests are based on the linearly independent pairwise comparisons among the estimated marginal means.

(25)

LAMPIRAN 7

DAFTAR RIWAYAT HIDUP

I. Identitas Pribadi

Nama

: dr. Meivina Ramadhani Pane

Tempat/Tgl Lahir : Medan / 15 Mei 1986

Suku/Bangsa

: Mandailing / Indonesia

Agama

: Islam

Alamat

: Jl. Suka Ramai No.4 Medan

II. Keluarga

Suami

: Lettu CKM dr. Esra Julianda Bangun

Anak

: Rafif Ravi Ahza Bangun

III. Pendidikan

SD Taman Harapan, Medan Tamat Tahun 1997

SLTP Sutomo 1, Medan Tamat Tahun 2000

SMU Sutomo 1, Medan Tamat Tahun 2003

Fakultas Keddokteran USU Tamat Tahun 2008

IV. Riwayat Pekerjaan

Dokter jaga RSU Bina kasih Medan tahun 2009

V. Perkumpulan Profesi

IDI Medan

PAPDI Sumut

VI. Journal Reading:

1. Pandit S, Chaudhuri AD, Datta SBS, Dey A, Bhanja P. Role of

pleural biopsy in etiological diagnosis of pleural effusion. Lung

India J. 2010;27:202-204

2. Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary

phosphate restriction & survival among hemodialysis patients. Clin

J Am Soc Nephrol. 2011;6:620-629

3. Mitwalli AH, Alam AA, Wakeel JS, Isnani AC. Dyslipidemia in

(26)

4. De-Madaria E, Soler-Sala G, Lopez-font I, et al. Influence of fluid

therapy on the prognosis of the acute pancreatitis: a prospective

cohort study. Am J Gastroenterol. 2011;106:1843-1850

5. Zirpoli JC, Lacerda HR, Albuquerqu VMG, et al. Angina pectoris in

patients with HIV/AIDS: prevalence & risk factors. Braz J Infect

Dis. 2012;16:1-8

6. Kabadi SM, Lee BK, Liu L. Joint effects of obesity and vit D

insufficiency on insulin resistance and type 2 diabetes. Diabetes

Journal. 2012;1-6

7. Al-Amran FG, Zwain AMH, Al-Mudhaffer AM. Autonomic cerebral

vascular respone to sildenafil in diabetic patient. Diabetology &

Metabolic syndrome. 2012;4:1-7

8. Herzig K, Purhonen A, Rasanen KM, Idziak J, Juvonen P, Phillps

R, Walkowiak J. Fecal elastase-1 levels in older individuals without

known gastrointestinal diseases or diabetes melitus. BMC

geriatrics. 2011;11:1-5

9. Xiaoshan S, Hongyun L. Anticoagulan therapy in patients with

COPD in the acute exacerbation stage. 2013;5(5):1367-1370

10. Fujiyoshi A, Murad MH, Luna M, Rosario A, Ali S, Paniagua D et

al. Metabolic syndrome & its components are underdiagnosed in

cardiology clinic. J Eval Clin Pract. 2011;17(1):78-83

VII. Tulisan Ilmiah

1. Pemberian kembali OAT pada penderita hepatitis imbas obat

akibat OAT.

2. Nefritis Lupus: klinis & diagnosis.

3. Akut miokard infark dengan elevasi segmen ST.

4. Penatalaksanaan kanker gaster.

5. Koinfeksi hepatitis C pada pasien HIV/AIDS.

6. Vitamin D dan kardiovaskular.

7. Depresi pada usia lanjut.

8. Kandung kemih hiperaktif pada usia lanjut.

9. Heparin induced trombocytopenia

.

(27)